Session Detail


Session Title: Concepts and Challenges in Bringing Next-Generation Sequencing to the Clinic
Session Type: Current Concepts and Controversies in Diagnostics, Therapeutics, and Prevention
Session Start/End Time: Monday, Apr 02, 2012, 10:30 AM -12:30 PM
Location: McCormick Place West (Level 1), Room W190
CME: CME-Designated
CME/CE Hours: 2
Session Description: Recent advances in next-generation sequencing (NGS) afford new opportunities for uncovering the compendium of somatic mutations in cancer. As the portfolio of targeted therapeutics also continues to grow, we are now facing a time in which real time identification of mutations can be collected during the course of clinical management. Thus, it is now possible to incorporate these genomic measurements into the decision process for the selection of possible therapies for cancer patients. In this session, we will provide examples of clinical studies that have been designed to leverage targeted and whole genome data. Study results will be presented, along with discussion of important lessons learned, as we continue to collect data on the relevance, feasibility, and improved design of these types of studies going forward.
Presentations:
Chairperson
John D. Carpten. TGen, Phoenix, AZ
Chairperson
Stephen B. Gruber. Univ. of Michigan, Ann Arbor, MI
A comprehensive genomic medicine approach identifies treatment options in advanced cancer patients: Results and lessons learned
Monday, Apr 02, 2012, 10:30 AM -10:50 AM
John D. Carpten. TGen, Phoenix, AZ
Discussion
Monday, Apr 02, 2012, 10:50 AM -10:55 AM
Personalized genomic analyses of human cancer
Monday, Apr 02, 2012, 11:20 AM -11:40 AM
Victor E. Velculescu. Johns Hopkins Kimmel Comp. Cancer Ctr., Baltimore, MD
Discussion
Monday, Apr 02, 2012, 11:15 AM -11:20 AM
Real-time sequencing of cancer and germline genomes for clinical trial optimization
Monday, Apr 02, 2012, 10:55 AM -11:15 AM
Stephen B. Gruber. Univ. of Michigan, Ann Arbor, MI
Discussion
Monday, Apr 02, 2012, 11:40 AM -11:45 AM
Regulatory approval and feasibility for genomic guided clinical trials
Monday, Apr 02, 2012, 11:45 AM -12:05 PM
Giselle L. Sholler. Van Andel Research Institute, Grand Rapids, MI
Discussion
Monday, Apr 02, 2012, 12:05 PM -12:10 PM
Panel Discussion
Monday, Apr 02, 2012, 12:10 PM -12:30 PM